UNSPSC 51432802: Ditekiren

This classification denotes an antihypertensive agent with the molecular formula C50H75N9O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5355S3W1IS, chemically known as tert-butyl (2s)-2-(((alphas)-alpha-(((1s)-1-(((1s,2s,4s)-2-hydroxy-1-isobutyl-5-methyl-4-(((1s,2s)-2-methyl-1-((2-pyridylmethyl)carbamoyl)butyl)carbamoyl)hexyl)carbamoyl)-2-imidazol-4-ylethyl)methylcarbamoyl)phenethyl)carbamoyl)-1-pyrrolidinecarboxylate but generally known as ditekiren, which bears US NIH Compound Identifier 5464201.

UNSPSC 51432802 Ditekiren (Commodity) is a pharmaceutical active ingredient code under which state and local governments procure emergency life-support medications and multi-source generic pharmaceuticals for healthcare delivery, fire rescue operations, and state health benefit programs. The work being solicited includes supply of branded and generic pharmaceutical products—including epinephrine, labetalol, adenosine, and diltiazem formulations—to be distributed through authorized wholesalers or delivered directly to municipal emergency services and state health agencies. Issuing bodies span municipal fire departments and rescue services, state health and human services agencies, and multi-state cooperative purchasing alliances. The scope includes not only product supply but also compliance with cGMP, Drug Supply Chain Security Act certification, OSHA Safety Data Sheets, FDA expiration-dating requirements, and accessibility documentation per WCAG 2.2 and Section 508 standards.

Activity is concentrated in Texas and Minnesota, with additional municipal solicitation in Florida. The City of Tampa's Purchasing Department issued an IFB (Solicitation 26P00188) in April 2026 for Advanced Life Support Medications to support Tampa Fire Rescue, specifying 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials, with a response deadline of April 8, 2026 and an estimated contract value of $40,000.00; the City designated this a Small Local Business Enterprise sheltered market with a 5 percent bid discount capped at $10,000. The Minnesota Department of Administration's Office of State Procurement issued an RFP through the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) for generic multi-source pharmaceuticals and OTC products (Solicitation S1070000015802) with a response deadline of March 26, 2026, requiring vendors to supply through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC, with contract effectiveness July 1, 2026. The Texas Health and Human Services Commission posted an RFI (HHS0017013) in April 2026 to explore direct-to-manufacturer prescription programs and vendor capacity for implementing therapeutic pharmacy initiatives outside traditional PBM and GPO channels.